Icalziss (Calcium Chloride Dihydrate)

Calcium chloride dihydrate dissociates in plasma to release calcium ions, raising extracellular calcium concentration. The increased calcium supports neuromuscular transmission, myocardial contractility, and various enzymatic processes, thereby correcting calcium deficits and stabilising cardiac and skeletal muscle function.

The dose of Icalziss is determined by the prescribing clinician based on the patient’s serum calcium level, weight, renal function and clinical condition. The healthcare professional calculates the required milliequivalents of calcium and selects the appropriate infusion rate and volume.

Safety data for calcium chloride dihydrate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Icalziss, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Icalziss provides calcium in the form of calcium chloride, which releases calcium ions rapidly when administered intravenously, making it suitable for acute correction of hypocalcemia. Oral calcium salts such as calcium carbonate act more slowly and are used for chronic supplementation, whereas Icalziss is intended for immediate, controlled IV replacement in hospital settings.

Icalziss should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze the solution, and discard any vial that shows particulate matter or discoloration before use.

Icalziss is administered intravenously by slow infusion through a suitable IV line, usually diluted in compatible crystalloid solutions as directed by the prescriber. Administration should be performed by trained healthcare personnel, with monitoring of vital signs and serum calcium levels throughout the infusion.

The most serious risks include severe hypercalcemia, which can lead to cardiac arrhythmias, hypotension, and neuromuscular irritability, as well as local tissue injury if the solution extravasates. Anaphylactic reactions, although rare, may also occur and require immediate medical intervention.

Icalziss should be avoided in patients with known hypersensitivity to calcium chloride, those with severe hypercalcemia, uncontrolled cardiac arrhythmias, or severe renal impairment unless closely monitored. It is also contraindicated when incompatible IV solutions are being co‑administered without proper compatibility testing.